In conclusion, we can show here for the first time that melanoma cells, which have already acquired resistance to BRAFV600E/K inhibitor monotherapy or to its combination with MEK inhibitors, can effectively and specifically be targeted by RSK inhibition. The gene discussed is RPS6KA3; the disease is melanoma.